Kidney-Sparing Approach Generates Responses in Low-Grade UTUC

Jason Harris
Published: Thursday, Jun 27, 2019
Seth P. Lerner, MD, FACS

Seth P. Lerner, MD, FACS

A novel formulation of the chemotherapy drug mitomycin demonstrated a 59% complete response (CR) rate among patients with unresectable low-grade upper tract urothelial cancer (UTUC), signaling the potential for a minimally invasive alternative to kidney removal for some individuals with this malignancy, according to findings from the phase III OLYMPUS trial.1

Results presented during the 2019 American Urological Association (AUA) Annual Meeting indicate that 42 of 71 patients treated with UGN-101 (mitomycin gel) achieved a CR. Among these responders, 24 of 27 patients who have undergone evaluations maintained a CR at ≥6 months.

In a subset of the overall study population with endoscopically unresectable tumors, 59% (20 of 34 patients) experienced a CR, including a CR lasting ≥6 months for 85% (17 of 20 patients).1 The most common adverse events (AEs) were urinary tract infection, ureteral narrowing, and stricture formation. No treatment- related fatalities were reported.2

The results suggest that minimally invasive chemoablation with UGN-101 may provide an alternative for the initial management of patients with low-grade UTUC, including those with endoscopically unresectable disease, study chair Seth P. Lerner, MD, FACS, and colleagues said in their AUA abstract.2

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication